◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Sun Pharma Advanced Research Company Limited (SPARC) Financial History

Name: Sun Pharma Advanced Research Company Limited (SPARC) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-10-22

Sun Pharma Advanced Research Company Limited (SPARC) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 279 employees. Its market capitalization is roughly ₹58 billion. In the fiscal year ended 2026-03-31, SPARC reported ₹392M in revenue and ₹15.5B in net income.

Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally.

Interactive charts & full statements → Open the SPARC valuation workbench →

SPARC Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹19.1B	₹392M	₹718M	₹756M	₹2.4B	—
Gross Profit	₹18.5B	(₹122M)	(₹382M)	(₹602M)	₹620M	—
Operating Income (EBIT)	₹16.1B	₹16.0B	(₹3.3B)	(₹4.1B)	(₹2.2B)	—
Net Income	₹15.8B	₹15.5B	(₹3.4B)	(₹3.9B)	(₹2.2B)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SPARC Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹399M	₹18.5B	₹84M	₹79M	₹96M	—
Gross Profit	₹190M	₹18.5B	(₹50M)	(₹62M)	(₹10M)	—
Operating Income (EBIT)	(₹362M)	₹17.7B	(₹592M)	(₹683M)	(₹548M)	—
Net Income	(₹208M)	₹17.6B	(₹804M)	(₹758M)	(₹519M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SPARC Free Cash Flow History

SPARC Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹21.7B	₹3.4B	₹5.2B	₹8.3B	—
Total Liabilities	₹8.3B	₹5.5B	₹3.9B	₹3.2B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SPARC viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

BLISSGVS · Bliss GVS Pharma Limited — ₹69 billion
4569 · KYORIN Pharmaceutical Co., Ltd. — JPY 63 billion
MOREPENLAB · Morepen Laboratories Limited — ₹63 billion
FDC · FDC Limited — ₹62 billion
INNOVACAP · Innova Captab Limited — ₹57 billion
4886 · ASKA Pharmaceutical Holdings Co.,Ltd. — JPY 57 billion
IOLCP · IOL Chemicals and Pharmaceuticals Limited — ₹53 billion
4554 · Fuji Pharma Co., Ltd. — JPY 49 billion

← SPAQ All “S” companies SPAX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.